Biomerica Inc Stock Price, News & Analysis

Biomerica, Inc. (Nasdaq: BMRA) has appointed Dr. Brian E. Lacy, a prominent gastroenterologist from Mayo Clinic, to its Scientific Advisory Board. Dr. Lacy will advise on the commercialization of the InFoods^® IBS product, a diagnostic-guided therapy designed to identify and eliminate specific foods that trigger Irritable Bowel Syndrome (IBS) symptoms. This therapy aims to provide personalized treatment without drug side effects. With IBS affecting 10-15% of American adults, Biomerica plans a nationwide launch of this innovative product.

Biomerica, Inc. (NASDAQ: BMRA) received regulatory clearances from the Kingdom of Saudi Arabia and UAE for two health products: the EZ Detect™ Colon Disease Test and the Aware® Breast Self Exam. These products will be launched through distribution partners in the Middle East and North Africa, targeting areas with high unmet needs. The EZ Detect test allows at-home screening for colorectal cancer, while the Aware device enhances breast cancer detection through self-exams. The company emphasizes the importance of accessible screening in improving health outcomes.

Biomerica (NASDAQ: BMRA) announced that its InFoods^® IBS clinical study data received the prestigious ACG Presidential Award at the 2022 Annual Scientific Meeting.

The study highlighted significant improvements in IBS symptoms, such as abdominal pain intensity, outperforming some existing drugs.

With no reported adverse effects, the findings were published in respected medical outlets, enhancing the visibility of InFoods^® IBS as a revolutionary approach to managing IBS symptoms, potentially impacting treatment protocols.

Biomerica, Inc. (NASDAQ: BMRA) announces a partnership with Walmart for the Aware® Breast Self Exam device, now available in over 2400 stores. This FDA-cleared device enhances sensitivity for self-exams, crucial for early breast cancer detection, which significantly improves survival rates. The product, retailing at $19.95, is expected to boost visibility and accessibility for women. CEO Zack Irani emphasized the importance of early detection and the role of their product in cancer survival. Discussions for further distribution partnerships are ongoing.

Biomerica, Inc. (BMRA) reported a 30% increase in net sales for Q3 2022, totaling $1.67 million compared to $1.26 million in the previous year. However, the company experienced a net loss of $2 million, or $0.16 per share, up from a $1.5 million loss the prior year. This loss is attributed to increased expenses, including higher salaries and legal fees. The company received patent allowances in Australia and Japan for its InFoods® Technology, which treats ADD/ADHD and depression, respectively. Biomerica aims to launch multiple products by year-end 2022, including an IBS test and an H. Pylori product.

Biomerica (NASDAQ: BMRA) recently announced that its Aware^® Breast Self Exam device and EZ Detect™ Colon Disease test are now available on Amazon. The Aware^® device enhances tactile sensitivity for breast self-exams, crucial for early detection of breast cancer, the most common cancer among women. Meanwhile, EZ Detect™ is a two-minute test for hidden blood in stool, an early sign of colorectal cancer. Increased availability on Amazon may enhance sales potential, addressing critical health issues with innovative home testing solutions.

Biomerica, Inc. (Nasdaq: BMRA) announced the upcoming launch of its InFoods® IBS test, expected before the end of 2022. This test will be offered through a CLIA-certified laboratory as a laboratory developed test (LDT). Following successful clinical trials at notable centers like Mayo Clinic, there is significant interest from gastroenterologists. Robert Carlson has been appointed Chief Commercial Officer to oversee the launch and commercialization strategy, aiming for national reimbursement and FDA authorization. Revenues from the InFoods IBS test are anticipated before year-end 2022.

Biomerica, Inc. (Nasdaq: BMRA) reported a remarkable 162% increase in revenues for fiscal 2022, totaling $18.9 million, compared to $7.2 million in fiscal 2021. The net loss also improved to $4.6 million from $7.5 million year-over-year. Significant sales growth was driven by COVID-19 antigen tests and OTC products. Important milestones include positive clinical trial results for its InFoods^® IBS product, six new patents granted, and successful completion of clinical studies for its H. pylori diagnostic test, with FDA clearance anticipated.

Biomerica, Inc. (BMRA) announced that its Aware® Breast Self Exam device will be available in Walmart stores and online, enhancing early breast cancer detection. The Aware® device, FDA-cleared, helps women increase sensitivity during self-exams, crucial since 80% of breast cancers are detected by women themselves. Walmart's extensive distribution network will boost visibility. Studies indicate the device is effective in detecting early breast changes. The product rollout aims to empower women with health management tools and facilitate monthly self-examinations.